Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for AMRN
+0.02 (1.09%)
Real-time:   1:07PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.79 - 1.87
52 week 1.24 - 2.80
Open 1.83
Vol / Avg. 359,604.00/770,560.00
Mkt cap 340.59M
P/E     -
Div/yield     -
EPS -0.81
Shares 183.10M
Beta 1.08
Inst. own 26%
Aug 4, 2016
Q2 2016 Amarin Corporation PLC Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 5, 2016
Amarin Corporation PLC Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
May 5, 2016
Q1 2016 Amarin Corporation PLC Earnings Release
May 5, 2016
Q1 2016 Amarin Corporation PLC Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -116.55% -140.91%
Operating margin -90.45% -118.53%
EBITD margin - -119.11%
Return on average assets -73.64% -67.23%
Return on average equity - -
Employees 210 -
CDP Score - -


2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 55
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Age: 52
Bio & Compensation  - Reuters
Michael J. Farrell Vice President - Finance (principal accounting officer and principal financial officer)
Age: 37
Bio & Compensation  - Reuters
Craig B. Granowitz M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 52
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Non-Executive Independent Director
Age: 50
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 73
Bio & Compensation  - Reuters